{
    "clinical_study": {
        "@rank": "82304", 
        "arm_group": [
            {
                "arm_group_label": "Cholecalciferol 50.000IU/week", 
                "arm_group_type": "Active Comparator", 
                "description": "patients will  receive  vitamin D3 (50.000 IU/week) for 24weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patients receive placebo in similar capsules of cholecalciferol for 24weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The potential role of vitamin D on disease susceptibility, activity and severity has been\n      considered for several autoimmune rheumatologic diseases include systemic lupus\n      erythematosus (SLE) .  Although, there are few studies of vitamin D supplementation in SLE\n      patients, especially in Juvenile Onset Systemic Lupus Erythematosus (JoSLE).\n\n      The objective of this study is to evaluate the effect of vitamin D supplementation\n      (cholecalciferol 50.000 international units (IU)/week for 24 weeks) on disease activity\n      (clinical and laboratory parameters), fatigue and bone mass."
        }, 
        "brief_title": "Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Lupus Erythematosus", 
        "condition_browse": {
            "mesh_term": [
                "Fatigue", 
                "Lupus Erythematosus, Systemic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a study 24-week, two arm, double blinded randomized clinical trial to evaluate the\n      effects of high-dose vitamin D3 supplementation compared with placebo, on activity disease,\n      fatigue and bone mass.\n\n      Sixty JoSLE patients  will be randomized to receive placebo  or vitamin D3 (50.000 IU/week)\n      for 24weeks. The patients return to visits in week 12 and week 24 for evaluation.  Study\n      will record clinical history, drugs in use, disease activity, and bone mass parameters."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent signed\n\n          -  4 of the 11 modified American College of Rheumatology (ACR) Revised Criteria for the\n             Classification of Systemic Lupus Erythematosus .\n\n          -  SLEDAI < 8 at Screening and at Baseline\n\n          -  Stable immunosuppressive dose prior to randomization.\n\n          -  Body Mass Index < 30\n\n          -  Able to swallow pills at randomization\n\n        Exclusion Criteria:\n\n          -  Refuse of the patient or the legal responsible\n\n          -  Use of  vitamin D2 or D3 supplementation\n\n          -  Significant renal insufficiency\n\n          -  Primary hyperparathyroidism (known)\n\n          -  History of nephrolithiasis (known)\n\n          -  Diabetes mellitus requiring insulin therapy\n\n          -  History of vertebral compression fractures (known)\n\n          -  Pregnancy\n\n          -  Use of  bisphosphonates"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "25 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01892748", 
            "org_study_id": "VITD59/11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cholecalciferol 50.000IU/week", 
                "intervention_name": "Cholecalciferol", 
                "intervention_type": "Drug", 
                "other_name": "Vitamin D3"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lupus", 
            "Juvenile", 
            "Cholecalciferol", 
            "Disease activity", 
            "Bone Mass", 
            "Fatigue", 
            "Safety"
        ], 
        "lastchanged_date": "July 3, 2013", 
        "location": {
            "contact": {
                "email": "glauceleao@gmail.com", 
                "last_name": "Glauce L Lima, MD", 
                "phone": "5511983262336"
            }, 
            "contact_backup": {
                "email": "rosamariarp@yahoo.com", 
                "last_name": "Rosa MR Pereira, MD PhD", 
                "phone": "551130617213"
            }, 
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "zip": "01246-903"
                }, 
                "name": "University of Sao Paulo - School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Onset Systemic Lupus Erythematosus.", 
        "overall_contact": {
            "email": "glauceleao@gmail.com", 
            "last_name": "Glauce L Lima, MD", 
            "phone": "5511983262336"
        }, 
        "overall_contact_backup": {
            "email": "rosamariarp@yahoo.com", 
            "last_name": "Rosa MR Pereira, MD PhD", 
            "phone": "551130617213"
        }, 
        "overall_official": [
            {
                "affiliation": "University of Sao Paulo - School of Medicine", 
                "last_name": "Rosa MR Pereira, MD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Sao Paulo - School of Medicine", 
                "last_name": "Glauce L Lima, MD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The change in Disease Activity Score (SLEDAI)", 
            "safety_issue": "Yes", 
            "time_frame": "baseline to week 12 and 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01892748"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Sao Paulo", 
            "investigator_full_name": "ROSA MARIA RODRIGUES PEREIRA", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "The change in Fatigue Score", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to week 12 and 24"
            }, 
            {
                "measure": "The change in Bone Mineral Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "baseline to week 12 and 24"
            }
        ], 
        "source": "University of Sao Paulo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ROSA MARIA RODRIGUES PEREIRA", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}